

SEARCHED UNDER 37 CFR 1.14(a)

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

REQUEST FOR		In re Application of								
<p style="text-align: center;">RECEIVED</p> <p>SEP 13 2001</p> <p>File Information Unit</p>		<table border="1"> <tr> <td>Application Number</td> <td>Filed</td> </tr> <tr> <td>08/487992</td> <td>1/7/95</td> </tr> <tr> <td>Group Art Unit</td> <td>Examiner</td> </tr> <tr> <td></td> <td></td> </tr> </table>	Application Number	Filed	08/487992	1/7/95	Group Art Unit	Examiner		
Application Number	Filed									
08/487992	1/7/95									
Group Art Unit	Examiner									

Paper No. 7721

**Assistant Commissioner for Patents
Washington, DC 20231**

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE) *5999705*

(A) referred to in United States Patent Number 5779028 column _____

(B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____ filed _____ on page _____ of paper number _____

(C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____ filed _____ or

(D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Please direct all correspondence to:


Signature

Signature

Typed or printed name

9/13/01 Date

Date

FOR PTO USE ONLY

Approved by:

Initials

1807

BEST AVAILABLE COPY

TIME ESTIMATE IS BASED ON AVERAGE TIME TO COMPLETE THIS FORM BY SOMEONE FAMILIAR WITH THE INFORMATION. THIS FORM IS FOR RMS TO THIS ADDRESS. SEND TO:

United States Patent [19]

Hallenbeck et al.

[11] Patent Number: **5,998,205**[45] Date of Patent: **Dec. 7, 1999****[54] VECTORS FOR TISSUE-SPECIFIC REPLICATION**

[75] Inventors: **Paul L. Hallenbeck**, Gaithersburg; **Yung-Nien Chang**, Cockeysville; **Yawen L. Chiang**, Potomac, all of Md.

[73] Assignee: **Genetic Therapy, Inc.**, Gaithersburg, Md.

[21] Appl. No.: **08/849,117**

[22] PCT Filed: **Nov. 28, 1995**

[86] PCT No.: **PCT/US95/15455**

§ 371 Date: **Jul. 1, 1997**

§ 102(e) Date: **Jul. 1, 1997**

[87] PCT Pub. No.: **WO96/17053**

PCT Pub. Date: **Jun. 6, 1996**

Related U.S. Application Data

[63] Continuation-in-part of application No. 08/487,992, Jun. 7, 1995, abandoned, which is a continuation-in-part of application No. 08/348,258, Nov. 28, 1994, abandoned.

[51] Int. Cl. ⁶ **C12N 15/00**

[52] U.S. Cl. **435/325; 514/44; 424/93.21; 536/23.1; 435/69.1; 435/320.1; 435/455**

[58] Field of Search **435/172.3, 320.1, 435/325, 455, 69.1; 514/44; 424/93.21; 536/23.1; 935/33, 52, 55, 66**

[56] References Cited**U.S. PATENT DOCUMENTS**

5,416,017	5/1995	Burton et al.	435/325
5,436,146	7/1995	Shenk et al.	435/455
5,585,096	12/1996	Martuza et al.	424/93.2
5,698,443	12/1997	Henderson et al.	514/44
5,728,379	3/1998	Martuza et al.	424/93.2
5,747,469	5/1998	Roth et al.	514/44
5,804,407	9/1998	Tamaki et al.	435/69.1

FOREIGN PATENT DOCUMENTS

WO95/12660	5/1995	WIPO .
WO96/18418	6/1996	WIPO .
WO96/34969	11/1996	WIPO .

OTHER PUBLICATIONS

Vile et al. (*Molecular Medicine Today*, vol. 4, 2:84-92, 1998).

Russel (*European Journal of Cancer*, vol. 30A, 8:1165-1171, Aug. 1994).

Smith et al. (*Human Gene Therapy*, 5:29-35, 1994).

Abe, M., and Kufe, D., "Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene," *Proc. Natl. Acad. Sci. USA* 90:282-286 (Jan. 1993).

Grooteclaes, M., et al., "The 6-Kilobase c-erbB2 Promoter Contains Positive and Negative Regulatory Elements Functional in Human Mammary Cell Lines," *Cancer Res.*, 54:4193-4199 (Aug. 1994).

Kovarik, A., et al., "Analysis of the Tissue-specific Promoter of the MUC1 Gene," *J. Biol. Chem.* 268:9917-9926 (May 1993).

Max-Audit, I., et al., "Transcriptional Regulation of the Pyruvate Kinase Erythroid-specific Promoter," *J. Biol. Chem.* 268:5431-5437 (Mar. 1993).

Morishita, K., et al., "A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression," *J. Biol. Chem.* 270:27948-27953 (Nov. 1995).

Nakabayashi, H., et al., "A Position-Dependent Silencer Plays a Major Role in Repressing α -Fetoprotein Expression in Human Hepatoma," *Mol. Cell. Biol.* 11:5885-5893 (Dec. 1991).

Pang, S., et al., "Prostate Tissue Specificity of the Prostate-Specific Antigen Promoter Isolated from a Patient with Prostate Cancer," *Human Gene Therapy* 6:1417-1426 (Nov. 1995).

Richards, C.A., et al., "Transcriptional Regulatory Sequences of Carcinomembryonic Antigen: Identification and Use with Cytosine Deaminase for Tumor-Specific Gene Therapy," *Human Gene Therapy* 6:881-893 (Jul. 1995).

Babiss, L.E. et al., "Cellular Promoters Incorporated into the Adenovirus Genome: Effect of Viral DNA Replication on Endogenous and Exogenous Gene Transcription," *J. Mol. Biol.* 193:643-650 (1987).

Blaese, R.M. et al., "In Situ Delivery of Suicide Genes for Cancer Treatment," *Eur. J. Cancer* 30A(8):1190-1193 (Aug. 1994).

Brown, D., "Gene Therapy 'Oversold' by Researchers, Journalists," *The Washington Post*, p. A22, Dec. 8, 1995.

Chellappan, S. et al., "Adenovirus E14, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product," *Proc. Natl. Acad. Sci. USA* 89:4549-4553 (1992).

(List continued on next page.)

Primary Examiner—Bruce R. Campbell

Assistant Examiner—Dave Trong Nguyen

Attorney, Agent, or Firm—Sterne, Kessler, Goldstein & Fox P.L.L.C.

[57] ABSTRACT

The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.

20 Claims, 5 Drawing Sheets

BEST AVAILABLE COPY